Weight loss at maximum dose
Separate trials — no head-to-head data exists between these two drugs. Results from 68-week clinical trials at maximum approved dose.
For a 240 lb person. Averages from separate clinical trials — no direct head-to-head comparison exists. Individual results vary substantially.
Monthly cost self-pay
Both are similar at entry level. With insurance, both are typically ~$25/month.
List prices and manufacturer self-pay programs. Insurance coverage varies.
No head-to-head trial exists. Oral semaglutide data comes from a Novo Nordisk trial; orforglipron data from two Eli Lilly trials. The comparison above uses data from separate studies, which is less definitive than a direct comparison.
Beyond weight loss
Daily routine
Heart benefit
Side effects
Neither profile is dramatically different from the other
These two pills differ on weight loss (oral semaglutide higher), convenience (orforglipron much simpler — no fasting), and cardiovascular evidence (semaglutide proven, orforglipron pending). Neither is universally better — they suit different priorities. A doctor can help you decide based on your medical history and schedule.
Common questions
Not sure where to start? Our 2-minute quiz can help.
Take the quiz →Next step most people take
Built with agentic AI tools and not a substitute for medical advice
Last reviewed: June 2026